Together with bioinformatic analysis of sequenced neuroblastoma patient samples and the developing human adrenal medulla, this couples HIF2α to low-risk neuroblastoma with a substantially better patient outcome and questions whether HIF2α is a neuroblastoma oncogene. The gene discussed is EPAS1; the disease is neuroblastoma.